Efficacy and safety of tacrolimus in the treatment of interstitial pneumonia with autoimmune features: a retrospective study
The results of this study demonstrate that tacrolimus significantly improves pulmonary inflammatory lesions, dyspnea symptoms, systemic inflammation levels, and facilitates steroid dose reduction in IPAF patients. Patients with baseline imaging features predominantly characterized by GGO and consolidation, or those positive for MSAs, may derive greater benefit from tacrolimus treatment. Further large-scale randomized controlled trials are warranted to validate its efficacy and safety.
Authors
- Xuemei Huang (ORCID: https://orcid.org/0000-0003-3583-5502)
- Anji Xiong (ORCID: https://orcid.org/0000-0002-4342-3738)
- Qinghua Yang (ORCID: https://orcid.org/0000-0003-1358-8096)
- Xinyue Cao (ORCID: https://orcid.org/0000-0002-1171-8697)
- Jie Luo
- Xi He
- Yanzao Zhao
Institutions
- North Sichuan Medical University (CN)
- Capital Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- Neijiang Normal University (CN)
- Beijing Anzhen Hospital (CN)
- Nanchong Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.3389/fphar.2025.1721639
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00